NEXAGON

(lufepirsen)

A first in class, patent protected, unmodified antisense

oligonucleotide that inhibits a cell membrane

hemichannel forming protein, connexin43 (Cx43). 


Cx43 is overexpressed after acute injury or in chronic

disease states leading to pathological, prematurely 

opened hemichannels, allowing ATP to enter the extracellular

space. Extracellular ATP triggers and perpetuates the immune

system's inflammasome pathway releasing multiple

pro-inflammatory cytokines resulting in microvascular

breakdown, vessel leak and limbal tissue ischemia.


NEXAGON inhibits Cx43 overexpression and the

inflammatory cascade, re-establishing limbal microvasculature

and promoting regeneration of the corneal epithelium.

 
MOA website.gif
 

CLINICAL TRIALS

NEXAGON FOR PED CTI

NEX-PED-005 (NCT04081103)

The ongoing Phase 2 randomized, double-masked, vehicle controlled study evaluates NEXAGON at two doses for the treatment of corneal Persistent Epithelial Defects due to severe ocular chemical and/or thermal injuries.

Persistent Epithelial Defect due to Chemical/Thermal Injury (PED CTI) is an orphan indication and Orphan Drug Designation (ODD) has been granted by the FDA.

Eye_Opening_edited_edited.jpg